CS
SAGE

Credit Suisse’s Sage Therapeutics SAGE Stock Holding History

Credit Suisse’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-82,000
Closed -$13M – 4223
2019
Q1 		$13M Buy
+82,000
New +$11.9M 0.01% 1086

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Credit Suisse's SAGE Position: Q1 2024 in Review

Credit Suisse reduced its Sage Therapeutics (SAGE) stake by 8.3% in Q1 2024, selling an estimated $215K and leaving 103,406 shares worth $1.94M. The position accounts for ﹤0.01% of the portfolio, ranked #1872.

Credit Suisse first reported a position in SAGE in Q4 2014 and has held it in 38 quarters since. The position peaked at $8.44M in Q1 2018. 205 funds tracked by Wall St. Rank hold SAGE as of Q1 2024.

  • Credit Suisse held 103,406 shares of Sage Therapeutics worth $1.94M as of Q1 2024.
  • Credit Suisse sold 9,312 Sage Therapeutics shares in Q1 2024, an estimated $215K.
  • Sage Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1872 holding.
  • Credit Suisse first reported a position in Sage Therapeutics in Q4 2014 and has held it in 38 quarters since.
  • Credit Suisse's Sage Therapeutics position peaked at $8.44M in Q1 2018.
  • 205 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.